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SUMMARY. Two liposomal formulations of doxorubicin (Caelyx® and Doxopeg®) were evaluated for
phospholipid content, doxorubicin concentration, liposomal size, zeta potential, osmolarity, phospholipid
peroxidation, in vitro release of the drug, pharmacokinetic profile, and cytotoxicity in cancer cell cultures.
Phospholipid concentration was not statistically different between formulations. Doxorubicin concentra-
tion was in the range of 2.0 mg/mL. Size and zeta potential were in the order of 80 nm and -37 mV, respec-
tively. Osmolarity and peroxidation in both formulations was similar and the in vitro drug release assay
indicated minimal release (2 %) of the doxorubicin content after 48 h. Pharmacokinetics parameters in
both formulations were very similar and no statistical difference was observed between them; the effect on
the growth inhibition in cell lines was also not different. Caelyx® and Doxopeg® are similar in terms of its
composition, physical parameters, stability, pharmacokinetics and growth inhibition in cancer cell lines. 
